Recombinant protein · Protein replacement: Tissue factor (F3) · developed by Laboratoire Franais Du Fractionnement Et Des Biotechnologies Socit Anonyme
Eptacog alfa is a recombinant analog of human coagulation factor VIIa. Complexed with tissue factor, it activates factor X to factor Xa, bypassing factor VIII and factor IX, to form a hemostatic clot at sites of bleeding. It is used to treat bleeding episodes in hemophilia with inhibitors and is being studied in intracerebral hemorrhage.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Nov 19, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04563520 | Phase 3 | Hemophilia A | Withdrawn | TAK |
| NCT07227246 | Phase 3 | Intracerebral Hemorrhage | Recruiting | NVO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Intracerebral HemorrhageHemophilia A
Updated Nov 15, 2026.